Anzeige
Mehr »
Freitag, 30.05.2025 - Börsentäglich über 12.000 News
Doppelt auf Infrastruktur gesetzt: Auf den Excel-Deal haben Investoren gewartet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9EJ | ISIN: US45258H1068 | Ticker-Symbol:
NASDAQ
29.05.25 | 21:56
2,230 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMIX BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
IMMIX BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur IMMIX BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IMMIX BIOPHARMA Aktie jetzt für 0€ handeln
DoImmix Biopharma - Positive newsflow continues for NEXICART-2206Immix Biopharma has announced a positive clinical update for the US-based Phase I/II NEXICART-2 trial, investigating lead CAR-T candidate NXC-201 as a potential treatment for relapsed/refractory (r/r)...
► Artikel lesen
23.05.Immix Biopharma accelerates NEXICART-2 trial enrollment2
23.05.Immix Biopharma, Inc.: Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2158- Patient enrollment exceeding expectations - - 14 U.S. sites actively enrolling; 10 U.S. sites added since last update - - Anticipate completing NEXICART-2 clinical trial ahead of schedule - LOS...
► Artikel lesen
22.05.Immix Biopharma, Inc.: Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis4
21.05.Immix Biopharma, Inc.: Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis2
19.05.Immix Biopharma, Inc. - 10-Q/A, Quarterly Report3
19.05.Immix Biopharma, Inc. - 10-K/A, Annual Report2
19.05.Immix Biopharma - Steady progress in Q125260Immix Biopharma's Q125 results reflect steady progress for NXC-201, its lead CAR-T candidate in clinical development to address amyloid light chain amyloidosis (ALA). During the quarter, Immix announced...
► Artikel lesen
08.05.Immix Biopharma, Inc. - 10-Q, Quarterly Report1
23.04.Immix Biopharma, Inc.: Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025115- Oral presentation Tuesday, June 3, 2025 in Chicago - LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical...
► Artikel lesen
04.04.Immix Biopharma - All eyes on NEXICART-2343Immix's FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis. Recent newsflow reflects heightened clinical activity...
► Artikel lesen
02.04.Artificial Intelligence Technology Solutions, Inc.: Immix and AITX's Robotic Assistance Devices (RAD) Announce Plans to Develop Strategic Integration to Advance Real-Time Incident Management with AI-Driven Automation447Las Vegas, Nevada--(Newsfile Corp. - April 2, 2025) - Immix®, the global provider of commercial central station and remote SOC software for managed video and security services, and Robotic Assistance...
► Artikel lesen
13.02.Immix Biopharma - NXC-201 receives FDA RMAT designation274Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the company's novel sterically optimized CAR-T treatment...
► Artikel lesen
10.02.Immix Biopharma, Inc.: Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis170FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation potentially streamlines the...
► Artikel lesen
15.01.Immix Biopharma - Shifting the ALA treatment paradigm with CAR-T368We review Immix Biopharma as it enters 2025, following the streamlining of its strategic priorities towards r/r ALA as the lead target indication for its CAR-T asset, NXC-201. The commencement of the...
► Artikel lesen
07.01.Immix Biopharma, Inc.: Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T332Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development...
► Artikel lesen
19.12.24Immix Biopharma, Inc.: Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis194All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow...
► Artikel lesen
16.12.24Immix Biopharma meldet vielversprechende Ergebnisse der CAR-T-Therapie4
16.12.24Immix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis178Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete...
► Artikel lesen
10.12.24Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis3
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1